Senseonics (SENS) Competitors

10x Genomics (NASDAQ:TXG) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.

Does the MarketBeat Community prefer TXG or SENS?

10x Genomics received 56 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 51.24% of users gave 10x Genomics an outperform vote while only 15.38% of users gave Senseonics an outperform vote.

Company	Underperform	Outperform
10x Genomics	Outperform Votes 62 51.24%	Underperform Votes 59 48.76%
Senseonics	Outperform Votes 6 15.38%	Underperform Votes 33 84.62%

Do analysts recommend TXG or SENS?

10x Genomics currently has a consensus target price of $19.79, suggesting a potential upside of 139.25%. Senseonics has a consensus target price of $2.00, suggesting a potential upside of 224.73%. Given Senseonics' stronger consensus rating and higher probable upside, analysts clearly believe Senseonics is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.35
Senseonics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Is TXG or SENS more profitable?

10x Genomics has a net margin of -29.90% compared to Senseonics' net margin of -362.30%. 10x Genomics' return on equity of -25.40% beat Senseonics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-29.90%	-25.40%	-19.69%
Senseonics	-362.30%	-842.25%	-67.99%

Does the media refer more to TXG or SENS?

In the previous week, 10x Genomics had 13 more articles in the media than Senseonics. MarketBeat recorded 19 mentions for 10x Genomics and 6 mentions for Senseonics. 10x Genomics' average media sentiment score of 0.69 beat Senseonics' score of 0.50 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Senseonics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, TXG or SENS?

10x Genomics has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Comparatively, Senseonics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Which has stronger valuation & earnings, TXG or SENS?

Senseonics has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Senseonics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$610.79M	1.66	-$182.63M	-$1.52	-5.44
Senseonics	$22.47M	17.87	-$60.39M	-$0.12	-5.13

Do institutionals & insiders hold more shares of TXG or SENS?

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 12.4% of Senseonics shares are held by institutional investors. 10.0% of 10x Genomics shares are held by company insiders. Comparatively, 3.6% of Senseonics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

10x Genomics beats Senseonics on 12 of the 19 factors compared between the two stocks.